A Phase I Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Topotecan at 4 mg/m2Administered Weekly as a 30-Minute Intravenous Infusion in Patients With Cancer

Autor: Jean T. Hartney, Donald W. Northfelt, Mitesh J. Borad, Kelly K. Curtis, P. P. Griffin, Tom R. Fitch, Peter F. Lebowitz, Roxanne C. Jewell, Jung W. Park
Rok vydání: 2010
Předmět:
Zdroj: The Journal of Clinical Pharmacology. 50:268-275
ISSN: 0091-2700
DOI: 10.1177/0091270009343699
Popis: Topotecan pharmacokinetics at higher infusion rates (4 mg/m2 over 30 minutes) have not been studied. The authors report a pharmacokinetics and safety study of this dose in advanced cancer patients. Sixteen patients were given a 4-mg/m2 topotecan infusion intravenously (IV) over 30 minutes weekly for 3 weeks, repeated every 28 days. Pharmacokinetics were determined after the first dose. Plasma concentrations of total topotecan were measured to derive CL, V(ss), C(max), t(max), t(1/2), AUC(0-t), and AUC(0-infinity). Plasma total topotecan concentrations decreased biexponentially, with a mean CL value of 20.6 L/h, V(ss) value of 101 L, and t(1/2) value of 5.0 h. Nine significant adverse events (all hematologic) were topotecan related. Grade 3 or less adverse events included anemia, thrombocytopenia, leukopenia, and fatigue. Pharmacokinetics of the 4-mg/m2 infusion of topotecan over 30 minutes are comparable to findings from studies of lower and higher doses. Toxicities are similar to previous reports.
Databáze: OpenAIRE